Multiple myeloma, cost-effectiveness analysis, anti-BCMA CAR-T
hematopoietic stem cell transplantation, fertility preservation, ovarian shielding, assisted reproductive technology, menstruation recovery, pregnancy
HTLV-1, stem cell transplantation, diseases other than ATL
blinatumomab, acute lymphoblastic leukemia, Philadelphia-chromosome negative, cost-effectiveness analysis